On November 22, 2021 EpiAxis Therapeutics reported that it will be taking its new corporate presentation to the J.P. Morgan 40th Annual Healthcare Conference (Press release, EpiAxis Therapeutics, NOV 22, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-heads-to-the-jp-morgan-40th-annual-healthcare-conference [SID1234595898]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The conference will be held in San Francisco from January 10-13, 2022.
"The J.P. Morgan 40th Annual Healthcare Conference is the largest and most informative health care investment symposium in the industry," said EpiAxis CEO Dr Jeremy Chrisp. "It connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community."
In 2021, public and private companies delivered presentations to more than 8000 conference participants.
For 2022, AusBiotech is hosting a virtual Australian Showcase during the conference, highlighting companies at the forefront of medical innovation. EpiAxis will share its new corporate presentation with global investors and potential partners at this conference.
Taiwan biotech forum
Together with AusBiotech, EpiAxis attended the Australia-Taiwan Biotech Investment & Partnership Forum in early November. Organised by the Australian Office Taipei and the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), the forum aimed to connect the biotech and pharma industries in the two nations.
More than 60 guests joined the forum, which was held during the BioTaiwan Exhibition, including several major biotech companies, venture capitalists, BIO industry members, event partners and journalists from bio magazines.
"It was exciting to share the latest updates from EpiAxis with industry and investors in Taiwan," said Dr Chrisp. "There is great potential for our epigenetics pipeline in the Asian market and we look forward to following up on the valuable connections that were made during the forum."